相关实验视频

Updated: Jun 27, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

在AL Amyloidosis中的免疫疗法-对未来的一

Arnon Haran¹, Iuliana Vaxman², Moshe E Gatt¹

¹Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel.

|April 27, 2024

概括

免疫疗法为轻链 (AL) 氨基化症,一种罕见的血细胞疾病提供了新的希望. 这些先进的治疗方法,包括CAR T细胞疗法,是有前途的,但需要对脆弱患者的毒性进行仔细管理.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

轻链 (AL) 氨基粉症是一种罕见的血细胞疾病,由于免疫球蛋白轻链错误折叠,导致器官损伤.
在历史上,AL氨基粉症的治疗策略一直遵循多发性骨髓瘤 (MM),但有延迟.
新兴的MM免疫疗法目前正在针对AL粉样性粉症进行研究.

研究的目的:

审查当前针对AL氨基粉症的免疫治疗策略.
讨论这些新型治疗方法的挑战和潜在好处.
突出未得到满足的需求和未来的方向在AL粉样化症的管理.

主要方法:

关于AL氨基粉症的免疫疗法当前文献的综述.
分析治疗方法,包括单克隆抗体,抗体与药物合物,双特异性抗体和CAR T细胞疗法.
讨论免疫媒介毒性 (CRS,ICANS) 和疗效.

主要成果:

免疫疗法显示出在AL氨基粉症中具有快速和深度血液学反应的潜力.
脆弱的AL粉样化症患者面临免疫中介毒性的风险.
获得这些疗法是有限的,需要国际合作和富有同情心的使用计划.

结论:

免疫疗法策略对改善AL粉样化症的结果具有显著的前景.
优化治疗顺序和减轻毒性对于患者的益处至关重要.
解决接入障碍和未得到满足的需求对于推进AL粉样化症护理至关重要.

关键词:

氨基粉症是什么?两种特异性的抗体.仿制性抗原受体T细胞的T细胞.免疫疗法免疫疗法轻链光链是什么意思血细胞分泌不良症血细胞分泌不良症

更多相关视频

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...